Hepatocellular shuttling and recirculation of sorafenib-glucuronide is dependent on Abcc2, Abcc3, and Oatp1a/1b

Aksana Vasilyeva, Selvi Durmus, Lie Li, Els Wagenaar, Shuiying Hu, Alice A. Gibson, John C. Panetta, Sridhar Mani, Alex Sparreboom, Sharyn D. Baker, Alfred H. Schinkel

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Recently, an efficient liver detoxification process dubbed "hepatocyte hopping" was proposed on the basis of findings with the endogenous compound, bilirubin glucuronide. According to this model, hepatocytic bilirubin glucuronide can follow a liver-to-blood shuttling loop via Abcc3 transporter-mediated efflux and subsequent Oatp1a/1b-mediated liver uptake. We hypothesized that glucuronide conjugates of xenobiotics, such as the anticancer drug sorafenib, can also undergo hepatocyte hopping. Using transporter-deficient mouse models, we show here that sorafenib-glucuronide can be extruded from hepatocytes into the bile by Abcc2 or back into the systemic circulation by Abcc3, and that it can be taken up efficiently again into neighboring hepatocytes by Oatp1a/1b. We further demonstrate that sorafenib-glucuronide excreted into the gut lumen can be cleaved by microbial enzymes to sorafenib, which is then reabsorbed, supporting its persistence in the systemic circulation. Our results suggest broad relevance of a hepatocyte shuttling process known as "hepatocyte hopping"- a novel concept in clinical pharmacology-for detoxification of targeted cancer drugs that undergo hepatic glucuronidation, such as sorafenib.

Original languageEnglish (US)
Pages (from-to)2729-2736
Number of pages8
JournalCancer Research
Volume75
Issue number13
DOIs
StatePublished - Jul 1 2015

Fingerprint

Glucuronides
Hepatocytes
Liver
Clinical Pharmacology
Xenobiotics
Bile
Pharmaceutical Preparations
sorafenib
Enzymes
Neoplasms

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Vasilyeva, A., Durmus, S., Li, L., Wagenaar, E., Hu, S., Gibson, A. A., ... Schinkel, A. H. (2015). Hepatocellular shuttling and recirculation of sorafenib-glucuronide is dependent on Abcc2, Abcc3, and Oatp1a/1b. Cancer Research, 75(13), 2729-2736. https://doi.org/10.1158/0008-5472.CAN-15-0280

Hepatocellular shuttling and recirculation of sorafenib-glucuronide is dependent on Abcc2, Abcc3, and Oatp1a/1b. / Vasilyeva, Aksana; Durmus, Selvi; Li, Lie; Wagenaar, Els; Hu, Shuiying; Gibson, Alice A.; Panetta, John C.; Mani, Sridhar; Sparreboom, Alex; Baker, Sharyn D.; Schinkel, Alfred H.

In: Cancer Research, Vol. 75, No. 13, 01.07.2015, p. 2729-2736.

Research output: Contribution to journalArticle

Vasilyeva, A, Durmus, S, Li, L, Wagenaar, E, Hu, S, Gibson, AA, Panetta, JC, Mani, S, Sparreboom, A, Baker, SD & Schinkel, AH 2015, 'Hepatocellular shuttling and recirculation of sorafenib-glucuronide is dependent on Abcc2, Abcc3, and Oatp1a/1b', Cancer Research, vol. 75, no. 13, pp. 2729-2736. https://doi.org/10.1158/0008-5472.CAN-15-0280
Vasilyeva, Aksana ; Durmus, Selvi ; Li, Lie ; Wagenaar, Els ; Hu, Shuiying ; Gibson, Alice A. ; Panetta, John C. ; Mani, Sridhar ; Sparreboom, Alex ; Baker, Sharyn D. ; Schinkel, Alfred H. / Hepatocellular shuttling and recirculation of sorafenib-glucuronide is dependent on Abcc2, Abcc3, and Oatp1a/1b. In: Cancer Research. 2015 ; Vol. 75, No. 13. pp. 2729-2736.
@article{36b3384f6f77461dbc65b96dcb447145,
title = "Hepatocellular shuttling and recirculation of sorafenib-glucuronide is dependent on Abcc2, Abcc3, and Oatp1a/1b",
abstract = "Recently, an efficient liver detoxification process dubbed {"}hepatocyte hopping{"} was proposed on the basis of findings with the endogenous compound, bilirubin glucuronide. According to this model, hepatocytic bilirubin glucuronide can follow a liver-to-blood shuttling loop via Abcc3 transporter-mediated efflux and subsequent Oatp1a/1b-mediated liver uptake. We hypothesized that glucuronide conjugates of xenobiotics, such as the anticancer drug sorafenib, can also undergo hepatocyte hopping. Using transporter-deficient mouse models, we show here that sorafenib-glucuronide can be extruded from hepatocytes into the bile by Abcc2 or back into the systemic circulation by Abcc3, and that it can be taken up efficiently again into neighboring hepatocytes by Oatp1a/1b. We further demonstrate that sorafenib-glucuronide excreted into the gut lumen can be cleaved by microbial enzymes to sorafenib, which is then reabsorbed, supporting its persistence in the systemic circulation. Our results suggest broad relevance of a hepatocyte shuttling process known as {"}hepatocyte hopping{"}- a novel concept in clinical pharmacology-for detoxification of targeted cancer drugs that undergo hepatic glucuronidation, such as sorafenib.",
author = "Aksana Vasilyeva and Selvi Durmus and Lie Li and Els Wagenaar and Shuiying Hu and Gibson, {Alice A.} and Panetta, {John C.} and Sridhar Mani and Alex Sparreboom and Baker, {Sharyn D.} and Schinkel, {Alfred H.}",
year = "2015",
month = "7",
day = "1",
doi = "10.1158/0008-5472.CAN-15-0280",
language = "English (US)",
volume = "75",
pages = "2729--2736",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "13",

}

TY - JOUR

T1 - Hepatocellular shuttling and recirculation of sorafenib-glucuronide is dependent on Abcc2, Abcc3, and Oatp1a/1b

AU - Vasilyeva, Aksana

AU - Durmus, Selvi

AU - Li, Lie

AU - Wagenaar, Els

AU - Hu, Shuiying

AU - Gibson, Alice A.

AU - Panetta, John C.

AU - Mani, Sridhar

AU - Sparreboom, Alex

AU - Baker, Sharyn D.

AU - Schinkel, Alfred H.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Recently, an efficient liver detoxification process dubbed "hepatocyte hopping" was proposed on the basis of findings with the endogenous compound, bilirubin glucuronide. According to this model, hepatocytic bilirubin glucuronide can follow a liver-to-blood shuttling loop via Abcc3 transporter-mediated efflux and subsequent Oatp1a/1b-mediated liver uptake. We hypothesized that glucuronide conjugates of xenobiotics, such as the anticancer drug sorafenib, can also undergo hepatocyte hopping. Using transporter-deficient mouse models, we show here that sorafenib-glucuronide can be extruded from hepatocytes into the bile by Abcc2 or back into the systemic circulation by Abcc3, and that it can be taken up efficiently again into neighboring hepatocytes by Oatp1a/1b. We further demonstrate that sorafenib-glucuronide excreted into the gut lumen can be cleaved by microbial enzymes to sorafenib, which is then reabsorbed, supporting its persistence in the systemic circulation. Our results suggest broad relevance of a hepatocyte shuttling process known as "hepatocyte hopping"- a novel concept in clinical pharmacology-for detoxification of targeted cancer drugs that undergo hepatic glucuronidation, such as sorafenib.

AB - Recently, an efficient liver detoxification process dubbed "hepatocyte hopping" was proposed on the basis of findings with the endogenous compound, bilirubin glucuronide. According to this model, hepatocytic bilirubin glucuronide can follow a liver-to-blood shuttling loop via Abcc3 transporter-mediated efflux and subsequent Oatp1a/1b-mediated liver uptake. We hypothesized that glucuronide conjugates of xenobiotics, such as the anticancer drug sorafenib, can also undergo hepatocyte hopping. Using transporter-deficient mouse models, we show here that sorafenib-glucuronide can be extruded from hepatocytes into the bile by Abcc2 or back into the systemic circulation by Abcc3, and that it can be taken up efficiently again into neighboring hepatocytes by Oatp1a/1b. We further demonstrate that sorafenib-glucuronide excreted into the gut lumen can be cleaved by microbial enzymes to sorafenib, which is then reabsorbed, supporting its persistence in the systemic circulation. Our results suggest broad relevance of a hepatocyte shuttling process known as "hepatocyte hopping"- a novel concept in clinical pharmacology-for detoxification of targeted cancer drugs that undergo hepatic glucuronidation, such as sorafenib.

UR - http://www.scopus.com/inward/record.url?scp=84942914440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84942914440&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-15-0280

DO - 10.1158/0008-5472.CAN-15-0280

M3 - Article

C2 - 25952649

AN - SCOPUS:84942914440

VL - 75

SP - 2729

EP - 2736

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 13

ER -